Vivos Therapeutics, Inc. (VVOS): Entry into a Material Definitive Agreement
Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth under Item 5.02 of this Current Report on Form 8-K regarding the Separation, Resignation and Executive Transition Agreement, dated as of July 31, 2026 (the “ Separation Agreement ”), between Vivos Th
How this was made
The 30-second read
Why it matters
The disclosed master services agreement appoints an engagement lead as CFO and principal financial officer effective the agreement’s effective date, and it outlines responsibilities for SEC filings, internal controls, and capital markets support.
Market read
This is a governance and reporting-support disclosure that may matter most to investors focused on SEC compliance readiness and internal control strengthening.
What to watch
Traders should look for the missing parts of the 8-K (full exhibits, any SOW terms, fees, and whether the engagement lead is replacing an existing CFO) because those details drive materiality.
Background
The SEC 8-K reports entry into a material definitive agreement and includes compensatory arrangements tied to officer/director matters (Item 1.01 and Item 5.02).
Ticker impact
Vivos Therapeutics entered a material definitive agreement appointing a managed CFO engagement lead effective July 31, 2026, via an 8-K Item 1.01/5.02.
Likely limited immediate price impact unless investors interpret it as a governance or listing-remediation signal; watch for follow-on disclosures on officer roles and any associated costs.
This is a primary SEC 8-K disclosure, but the excerpted agreement text is largely boilerplate and does not include financial terms, termination triggers beyond cause, or explicit operational outcomes.
Market effects
Highlights the use of fractional CFO providers by microcap issuers for SEC reporting, internal controls, and capital markets support.
None indicated.
None indicated.
Counterpoint
The agreement may simply be a cost-efficient way to strengthen SEC reporting and internal controls, not a sign of trouble, so the market reaction could be muted.
Key entities
- public_companyVivos Therapeutics, Inc.
Nasdaq-listed issuer (ticker VVOS) that entered the master services agreement and reported it on Form 8-K.
- service_providerThe CFO Portal, LLC
Provider of managed CFO and finance-and-accounting leadership services under the agreement.
- individualRoman Franklin
Named engagement lead appointed as CFO and principal financial officer effective on the agreement’s effective date, per the excerpt.
